Trial intelligence / Profile preview

Phase III study of N-803 + tislelizumab + docetaxel versus docetaxel alone in advanced or metastatic NSCLC with acquired resistance to immune checkpoint inhibitors

CTR20262723Phase 3Active

Sponsor

ImmunityBio, Inc.

Start

Jul 2026

Modality

Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules

Countries

1